MRK
Merck & Co., Inc.
NYSE · Healthcare · Drug Manufacturers - General · US
$148.88
+2.91%Aug 3, 2026, 18:02 UTC
Merck & Co. presented its HIV treatment and prevention strategy at an investor event, highlighting Phase III results for a once-weekly oral HIV regimen and plans for a monthly oral PrEP candidate.
Source:Jul 31, 2026, 18:10 UTC
Merck launched subcutaneous Qlex, extending the lifecycle of Keytruda.
Source:Jul 31, 2026, 14:30 UTC
Rappta Therapeutics, founded by Goutham Narla, was acquired by Merck, which will develop its treatment for endometrial and lung cancer.
Source:Jul 31, 2026, 09:15 UTC
Universal Corporation Limited (UCL) of Kikuyu, Kenya, was selected by Merck as one of seven manufacturers worldwide to produce alimatravir, an experimental once-monthly HIV prevention pill, under a licensing agreement announced at the 26th International Aids Conference in Rio de Janeiro.
Source:Jul 29, 2026, 15:04 UTC
Merck announced its fourth-quarter 2026 dividend on July 29, 2026.
Source:Jul 27, 2026, 01:54 UTC
Aurobindo Pharma Ltd has entered into a non-exclusive voluntary licensing agreement with MSD (Merck & Co., Inc.) for an HIV drug.
Source:Jul 24, 2026, 19:38 UTC
Qnity Electronics, Inc. appointed Katherine (Kate) Dei Cas as President of its Semiconductor Technologies business segment, effective August 3.
Source:Jul 24, 2026, 10:45 UTC
Merck has licensed its experimental oral HIV drug to generic manufacturers in 129 countries.
Jul 21, 2026, 14:00 UTC
Gilead Sciences and Merck & Co. announced phase 3 clinical trial results for their two-drug combination lenacapavir and islatravir, positioning it as the first complete weekly oral HIV treatment.
Source:Jul 20, 2026, 01:05 UTC
Merck Animal Health's needle-free intradermal vaccine Porcilis® M Hyo ID ONCE® received approval from China's Ministry of Agriculture and Rural Affairs for the prevention of disease caused by Mycoplasma hyopneumoniae infection in pigs.
Source:Jul 17, 2026, 00:00 UTC
GSK discontinues development of camlipixant, an experimental chronic cough medicine, after mixed Phase 3 data.
Jul 16, 2026, 17:49 UTC
The U.S. Food and Drug Administration approved Merck's first-of-its-kind cholesterol-lowering pill Lipfendra for high-risk patients.
Jul 16, 2026, 11:30 UTC
Medicus Pharma received positive FDA feedback and central IRB approval for its optimized Phase 2 study of Teverelix in acute urinary retention.
Jul 15, 2026, 17:25 UTC
Merck & Co. released topline data from the Phase 3 KEYNOTE‑C93 trial showing Keytruda outperforms chemotherapy in advanced endometrial cancer.
Source:Jul 15, 2026, 07:45 UTC
Kelun-Biotech announced that its Phase 3 clinical study (OptiTROP-Lung06) of sac-TMT combined with Keytruda for first-line treatment of PD-L1-negative advanced or metastatic NSCLC met its primary endpoint.
Source:Jul 13, 2026, 17:00 UTC
Cosmos Health entered into a five-year partnership with Libytec to commercialize DIABIT-IS X in Greece, with Cosmos Health supplying the product and Libytec handling distribution and promotion.
Source:Jul 10, 2026, 16:15 UTC
The U.S. House Select Committee on the Chinese Communist Party launched a bipartisan investigation into five major American pharmaceutical companies over clinical trials conducted in China, including at hospitals linked to the People's Liberation Army and in Xinjiang province, sending letters demanding records by July 17.
Jul 9, 2026, 03:47 UTC
Merck announced that the FDA granted Breakthrough Therapy designation to enpatoran for the treatment of lupus with active cutaneous manifestations.
Source:Jul 2, 2026, 12:00 UTC
Lupin has appointed Bijender Vats as senior vice president and head of human resources.
Source:Jul 2, 2026, 02:30 UTC
Merck Animal Health will launch Senstan® in China.
Source:Jul 2, 2026, 02:30 UTC
China's Ministry of Agriculture and Rural Affairs approved the API change for Nuflor® (florfenicol injection), allowing its return to the Chinese market.
Source:Jun 29, 2026, 12:30 UTC
Merck acquired Modifi Biosciences in a deal worth up to $1.3 billion.
Source:Jun 25, 2026, 15:06 UTC
Merck received European Union approval for the combination of Keytruda and Padcev in patients with resectable muscle-invasive bladder cancer who are ineligible for cisplatin-based chemotherapy.
Source:Jun 24, 2026, 10:45 UTC
The European Commission approved KEYTRUDA plus Padcev as a treatment for adults with cisplatin-ineligible resectable muscle-invasive bladder cancer.
Jun 16, 2026, 12:00 UTC
Protillion Biosciences announced a multi-target discovery collaboration and license agreement with Merck.
Source:Jun 9, 2026, 20:36 UTC
Gilead and Merck report positive phase III results for once-weekly HIV regimen islatravir/lenacapavir.
Source: